It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a
significant survival benefit from the sorafenib treatment, which is currently regarded as a first …

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma
(HCC), has opened a window of hope after searching for effective agents to combat HCC for …

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …

Liver cancer is highly malignant and insensitive to cytotoxic chemotherapy and is associated
with very poor patient prognosis. In 2007, the small-molecule targeted drug sorafenib was …

Hepatocellular carcinoma (HCC) is one of the most severe diseases worldwide. For the
different stages of HCC, there are different clinical treatment strategies, such as surgical …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality
worldwide. Sorafenib is the first multi-tyrosine kinase inhibitor approved for HCC and it has …

Despite advances in biomedicine, the incidence and the mortality of hepatocellular
carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages …

Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and
angiogenesis and promotes tumor cell apoptosis. It was approved by the FDA for the …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide,
and prognosis remains unsatisfactory when the disease is diagnosed at an advanced stage …